In contrast, a recent Canadian population-based cohort study detected a higher risk for hospitalization with rhabdomyolysis (RR = 2.17, 95 % CI:1.04–4.53), acute kidney injury (RR = 1.78, 95 % CI, 1.49–2.14) and for all-cause mortality (RR = 1.56, 95 % CI: 1.36–1.80) in older people associated with co-prescription of a CYP3A4 metabolized statin with clarithromycin or erythromycin compared with azithromycin. Here, CYP3A4 is linked to rhabdomyolysis.